Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sanofi Sees Cemiplimab As Path To Relevance In Immuno-Oncology

Dec 13 2017

• By Joseph Haas

Cancer cells

Related Content

Sanofi Oncology Strategy: A New Lease On Cancer R&D

Aug 10 2015

Roche Powers Forward With First-Line Tecentriq In Advanced NSCLC

Dec 07 2017

Sanofi Ready To Pull The Plug On Regeneron 'Life Support'

Sep 19 2017

Keeping An Eye On Regeneron: What's Next To Drive Growth

Nov 08 2017

Related Companies

Sanofi

Regeneron Pharmaceuticals, Inc.

Merck & Co., Inc.

Bristol Myers Squibb Company

Roche Holding AG

Genentech, Inc.

Additional Topics

ImmunoOncology Clinical Trials Biologics Business Strategies BioPharmaceutical Cancer

More from Immuno-oncology

More from Anticancer

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window